Navigation Links
A novel computational model -- how Parkinson's medications affect learning and attention
Date:1/20/2010

Newark, NJ A new brain-based computational model is helping to understand how Parkinson's disease and dopamine medicationsused to treat motor symptoms caused by the disease can affect learning and attention.

As reported in a forthcoming article in the Journal of Cognitive Neuroscience, http://www.mitpressjournals.org/doi/pdf/10.1162/jocn.2010.21420, a new computational model, developed by Drs. Ahmed Moustafa and Mark Gluck, at the Center for Molecular and Behavioral Neuroscience at Rutgers University, Newark, has shown how Parkinson's disease affects attentional performance during learning.

The same model also shows that dopamine medications enhance attentional performance in Parkinson's patients in agreement with past observations. Future lab experiments with Parkinson's patients will be conducted by Moustafa and Mark Gluck to test further model predictions.

Parkinson's is a disease that mainly affects dopamine levels in a brain area known as the basal ganglia, which is important for motor control. Hence, damage to this area leads to movement disorders, including shaking and difficulty moving--key symptoms of Parkinson's disease.

Over the past two decades, it became known to neurologists and experimental neuroscientists that Parkinson's disease also affects non-motor functions, including memory, learning, and attention. Impairment in these processes affect the quality of life of the patients, thus, understanding the neural basis of motor and non-motor dysfunction in Parkinson's disease is equally important.

Dopamine is also projected to other parts of the brain, including the prefrontal cortex, an area important for higher-level thinking, decision making, and attention. Dopamine projected to the prefrontal cortex is also reduced in Parkinson's disease, as reported in many experimental studies with humans and animal models of Parkinson's disease.

According to Moustafa and Gluck, until recently, existing computational models of Parkinson's disease ignored any role played by dopamine in the prefrontal cortex. Moustafa and Gluck have designed a new computational model that shows how dopamine in the prefrontal cortex is important for attentional performance, and how dysfunction of dopamine in the prefrontal cortex can explain many of the non-motor deficits seen in Parkinson's patients.

"Computational models are increasingly being used in the neurosciences and neurology to understand how neurological disorders affect brain and behavior," said Moustafa. "This relatively new fieldknown as computational neuroscience is promising to aid in designing new pharmacological and surgical intervention tools to treat neurological and psychiatric diseases."


'/>"/>

Contact: Helen Paxton
paxton@andromeda.rutgers.edu
973-353-5262
Rutgers University
Source:Eurekalert

Related medicine news :

1. TD2 and Critical Outcome Technologies Inc. develop novel anti-cancer drug
2. New human reproductive hormone could lead to novel contraceptives
3. Researchers discover novel method for detecting MIRCERA
4. Novel detection method unmasks circulating breast cancer cells
5. Turning metal black more than just a novelty
6. Engineers, doctors at UCLA develop novel material that could help fight arterial disease
7. Novel Technology in Treating Chronic Sinus Infections Available at Baptist
8. Novel K-anonymity algorithm safeguards access to data
9. Tulane Cancer Center to begin novel clinical trial for late-stage prostate cancer drug
10. Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
11. Dallas Facial Plastic Surgeon Publishes Cutting-Edge Novel Approach To Facelift Technique
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Florida (PRWEB) , ... February 05, 2016 , ... Steven ... event he has completed every year since it started in 2003. This year, he ... the attention of fellow runners and NBA team the Miami Heat. , This Sunday, ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... company's lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider capability to ... design and manufacturing not only reduce the weight of the unit, they also ...
(Date:2/5/2016)... ... 2016 , ... Successful recruitment and retention efforts, new collaborations ... have all marked the last 12 months at Roswell Park Cancer Institute (RPCI). ... oldest cancer center, Candace S. Johnson, PhD, outlined the many accomplishments of her ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular ... Louisiana Kitchen restaurants, launched the 14th annual “Appetite for a Cure” campaign on ... muscular dystrophy, ALS and related diseases that severely limit strength and mobility. ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016 Amgen (NASDAQ: AMGN ) will present ... Conference at 9:15 a.m. ET on Wednesday, Feb. 10, 2016, ... W. Meline , executive vice president and chief financial officer ... the presentation can be accessed from the Events Calendar on ... the webcast will also be available on Amgen,s website for ...
(Date:2/5/2016)... Feb. 5, 2016  ivWatch, a medical devices company, is ... Award granted by Governor Terry McAuliffe,s office. ivWatch ... February 25th at an event to be held at the ... award honors professionals and business that have made significant contributions ... Logo - http://photos.prnewswire.com/prnh/20160205/330117LOGO ...
(Date:2/5/2016)... MILTON, Ontario , Feb. 5, 2016  Aralez ... business combination of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada ... of POZEN and shareholders of Tribute. The combined company ... specialty pharmaceutical company with operations in Canada ... the United States . Under the terms ...
Breaking Medicine Technology: